c-Met (Cytoplasmic) Rabbit anti-Human, Polyclonal, Proteintech

Description

• In Western blot, this antibody produces bands of unknown identity at 55 and 100 kDa
• The Mesenchymal Epithelial Transition (MET) receptor belongs to a family of receptor tyrosine kinases (RTKs)
• Dyregulation of the MET signaling pathway occurs in wide range of human tumors
• The MET receptor is a glycoprotein heterodimer consisting of an extracellular alpha-subunit linked to transmembrane beta-subunit by a disulfide bond
• The MET receptor is widely expressed on the surface of epithelial and endothelial cells
• MET ligand is known as the hepatocyte growth factor (HGF), also called the scatter factor (SF)
• HGF/SF is a serine protease and produced in cells of mesenchymal origin
• HGF is secreted as a s ingle chain, biologically inactive protein which is further processed into its mature form by a cleavage process catalyzed by extracellular proteases
• MET and its ligand HGF are involved in several normal and pathological processes, such as fetal liver, placenta and muscle development, as well as development of the nervous system
• MET signal transduction is involved in tumor growth, invasion, resistance to therapy, angiogenesis and specially in the generation and maintece of cancer stem cells (CSCs)
• Upon HGF binding, the MET receptor at the plasma membrane forms a stable dimer of two molecules of MET which leads to subsequent activation and trans-phosphorylation of the two tyrosine residues in the catalytical regions Y1234 and Y1235, followed by trans-phosphorylation of two docking tyrosines (Y1349 and Y1356) in the carboxy-terminal site
• These phosphorylations enable MET to bind to multiple substrates and activate a variety of signaling pathways including MAPK, PI3K-AKT cascades, STAT and NF-kappaB.